Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to assess whether treatment with GC811007 would arrest the decline in renal function and the associated progression of diabetic retinopathy, peripheral neuropathy and autonomic neuropathy in patients with Type 2 diabetes mellitus.

Trial Profile

Study to assess whether treatment with GC811007 would arrest the decline in renal function and the associated progression of diabetic retinopathy, peripheral neuropathy and autonomic neuropathy in patients with Type 2 diabetes mellitus.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trientine (Primary)
  • Indications Diabetic nephropathies; Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms INFO-RENAL
  • Sponsors Protemix Corporation
  • Most Recent Events

    • 25 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top